Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings-Reference-Cited by-同舟云学术

Frequency of Approval and Marketing of Biosimilars With a Skinny Label and Associated Medicare Savings

Published:2023-01-01 Issue:1 Volume:183 Page:82
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Egilman Alexander C.¹,Van de Wiele Victor L.¹,Rome Benjamin N.¹,Darrow Jonathan J.¹,Tu S. Sean¹²,Kesselheim Aaron S.¹,Sarpatwari Ameet¹

Affiliation:

1. Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

2. West Virginia University College of Law, Morgantown

Abstract

This cohort study assesses the frequency of approval and marketing of skinny-label biosimilars and their savings to Medicare.

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2798552/jamainternal_egilman_2022_ld_220042_1672531909.49002.pdf

Reference6 articles.

1. The characteristics of patents impacting availability of biosimilars.;Van de Wiele;Nat Biotechnol,2022

2. Frequency of first generic drug approvals with “skinny labels” in the United States.;Walsh;JAMA Intern Med,2021

3. A court decision on “skinny labeling”: another challenge for less expensive drugs.;Walsh;JAMA,2021

4. Projected US savings from biosimilars, 2021-2025.;Mulcahy;Am J Manag Care,2022

5. Mulcahy? AW, Hlavka? JP, Case? SR. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. RAND Corporation. Published 2017. Accessed September 21, 2022. https://www.rand.org/pubs/perspectives/PE264.html

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biosimilar Uptake In The US: Patient And Prescriber Factors;Health Affairs;2024-08-01

2. Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label;Annals of Internal Medicine;2024-06

3. Monoclonal antibody biosimilars for cancer treatment;iScience;2024-06

4. A “Method of Use” to Prevent Generic and Biosimilar Market Entry;New England Journal of Medicine;2023-02-09

5. Savings Associated With “Skinny Label” Biosimilars;JAMA Internal Medicine;2023-01-01